C4X Discovery acquires Adorial Pharma
Apr 27, 2016
27 April 2016
Manchester-headquartered drug researcher C4X Discovery has acquired the developer of a mathematical tool that identifies the causes of disease that can be targeted by pharmaceuticals. C4X has bought Adorial Pharma, the developer of Taxonomy3. Both businesses were funded by Innovate UK. Adorial's technology, which is based on novel mathematics, analyses publicly available genetic datasets generated across broad therapeutic areas and is able to mine more genetic insights than conventional methods. This can lead to the discovery and validation of novel drug targets with direct genetic support, which is known to increase the probability of successful drug launch. Dr Clive Dix, executive chairman of C4X Discovery, said: "With Adorial, we now not only have the ability to create the best-in-class molecules against any known therapeutic target using C4XD's approach to ligand-based drug discovery, but also the ability to identify our own highly relevant and unique targets using Taxonomy3. "
Dr Alun McCarthy, former chief executive of Adorial and now vice-president of novel target biology and genomics at C4X, said: "The combination of Adorial's ability to identify novel drug targets with C4X's ability to rapidly generate molecules against these targets creates an extremely powerful drug discovery engine. "
Adorial was founded by Dr McCarthy and his colleague Dr Olivier Delrieu and was a spin-out in 2014 from drug discovery company PGXIS.